coagulation factor VII

coagulation factor VII

 Factor VII, see there.
References in periodicals archive ?
In the initiation phase, which is the first phase, coagulation starts when the vasculature is injured and subendothelial cells expose tissue factor (TF), which is the key initiator of haemostasis, that binds to coagulation factor VII, leading to its activation to FVIIa.
Exposure of the blood to tissue factor triggers the extrinsic coagulation pathway whose function is monitored by the PT through interaction of tissue factor with activated coagulation factor VII (FVII).
The increased INR values with Neoplastin R during unstable anticoagulation, such as in the initial phase of oral anticoagulation treatment, could be explained by fluctuations in coagulation factor VII (FVII) concentrations owing to the low half-life of FVII.
Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-control.
After each repast, researchers measured concentrations of coagulation factor VII (FVII), a protein that triggers production of a clotting agent in the blood.
In this model, all clotting is initiated by the combination of tissue factor and activated coagulation factor VII (FVIIa).
Coagulation factor VII (FVII) is a vitamin K-dependent protease that plays a key role in the initiation of the activation of the blood coagulation cascade.
Active ingredient and quantity: Coagulation factor ii 400-960 iu / vial coagulation factor vii 200-500 iu / vial coagulation factor ix 400-620 iu / vial coagulation factor x 440-1,200 iu / vial other active ingredients: Protein c 300-900 iu / vial and protein s 240-760 iu / vial pharmaceutical form: Vial packaging conditions: Unit dose maximum unit price: 153 eur / vial (taxes not included) number of units planned: 450 vials estimated maximum budget: Eur 68 850 (first year of contract).
We developed a pyrosequencing-based genotyping protocol for parallel analysis of the [beta]-fibrinogen (-455G/A and -854 G/A), prothrombin (G20210A), coagulation factor V Leiden (G1691; Arg506G1n), coagulation factor VII (-401G/T and -402 G/A), coagulation factor XIII (G163T; Val34Leu), plasminogen activator inhibitor-1 (PAI-1; -675 4G/5G), methylenetetrahydrofolate reductase (MTHFR; C677T; Ala222Val), glycoprotein IIIa (GPIIIa; C1565T; Leu33Pro; also known as PlA1/ PlA2), and endothelial nitric oxide synthase (eNOS; G894T; G1u298Asp) polymorphisms, together with the cytochrome P450 2C9 [CYP2C9*1 (wild type)], CYP2C9*2 (C430T; Cys144Arg), CYP2C9*3 (A1075C; Ile359Leu), and CYP2C9*4 (T1076C; Ile359Thr) isoforms, which modulate the effect of warfarin in antithrombotic therapy.
Contract awarded for event 2238/16 recombinant coagulation factor vii assets, dust and solution for use parenteral rt 1mg (50kui).
The dysfunction of coagulation factor VII Padua results from substitution of arginine-304 by glutamine.

Full browser ?